Genetic Tailoring of Pharmacotherapy in Heart Failure: Optimize the Old, While We Wait for Something New

Talameh, Jasmine A.; McLeod, Howard L.; Patterson, J. Herbert

doi:10.1016/j.cardfail.2012.01.002

Cited by 23 publications

(18 citation statements)

References 74 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, no study has evaluated the attitudes of patients with advanced cardiac disease or having received cardiac transplantation. Given the many recent publications highlighting the fact that genetic information could be useful to optimize heart failure (HF) 4,15,16 and transplant patients' pharmacotherapy, [17][18][19] we have designed a project with the aim of comparing the opinions, hopes and concerns regarding pharmacogenomics among healthy volunteers, patients with HF and heart transplant recipients. As personal health-related experiences such as previous use of medical tests or history of side effects have a positive impact on the general public's attitudes towards pharmacogenomics, 6,7,13,20 we hypothesized that HF and heart transplant patients would be more willing to undergo pharmacogenomic testing than healthy individuals.…”

Section: Introductionmentioning

confidence: 99%

Opinions, hopes and concerns regarding pharmacogenomics: a comparison of healthy individuals, heart failure patients and heart transplant recipients

et al. 2014

View full text Add to dashboard Cite

It is not yet known whether healthy individuals and patients with a chronic disease have similar attitudes towards pharmacogenomics. Thus we conducted a survey of 175 healthy volunteers, 175 heart failure (HF) patients and 100 heart transplant recipients to compare their opinions on this subject. Most participants (>90%) stated that they would accept pharmacogenomic testing and expressed high hopes regarding its potential applications. Overall, interest for pharmacogenomics was shared equally among the three groups. In contrast, after adjusting for age, gender, education and income, healthy individuals were more likely to voice concerns about potential employment (P=0.008 vs HF, odds ratio (OR)=2.93, confidence interval (CI)=1.33-6.47; P=0.010 vs Transplant, OR=2.46, CI=1.24-4.90) and insurance discrimination (P=0.001 vs HF, OR=5.58, CI=2.01-15.48; P<0.001 vs Transplant, OR=4.98, CI=2.03-12.21) and were possibly more worried by confidentiality issues. These findings highlight the need for strict legislation and proper educational strategies directed at the general population to facilitate the clinical implementation of pharmacogenomics.

show abstract

Section: Introductionmentioning

confidence: 99%

Opinions, hopes and concerns regarding pharmacogenomics: a comparison of healthy individuals, heart failure patients and heart transplant recipients

et al. 2014

View full text Add to dashboard Cite

show abstract

“…The audience again considered the patient case using the concepts presented during presentation. The future directions of cardiovascular pharmacogenetics introduced β-blocker efficacy in heart failure [22,23], and the seminar concluded with a summary of all of the information presented.…”

Section: Pharmacogenetic Educationmentioning

confidence: 99%

Physicians’ Attitudes Toward Pharmacogenetic Testing Before and After Pharmacogenetic Education

Luzum

2016

Per. Med.

View full text Add to dashboard Cite

Aim:Our aim was to evaluate physicians' attitudes toward pharmacogenetic testing before and after pharmacogenetic education. Methods: In total, 12 physicians (∼40% response rate) completed a survey with eight questions on 10-point scales on their attitudes toward pharmacogenetic testing before and after a 1-h grand rounds presentation on pharmacogenetics. Differences in question scores overall, among training levels (resident/fellow/attending), and specific drugs (clopidogrel/simvastatin/warfarin) were assessed using Wilcoxon signed-rank and exact Kruskal-Wallis tests. Results & conclusion: The scores for all eight questions increased, with statistically significant (p < 0.05) increases for four out of eight questions. The scores were similar among training levels, but the postscores for clopidogrel were significantly higher than for simvastatin and warfarin. In conclusion, brief pharmacogenetic education can significantly affect physicians' attitudes toward pharmacogenetic testing.

show abstract

“…Clinical response to HF medication varies significantly from patient to patient, 45 and pharmacogenomic information has the potential to help tailor HF treatment. Among many single nucleotide polymorphisms in the β-adrenergic receptor genes, Arg389Gly in β-1 adrenergic receptor (ADRB1) has been most widely investigated.…”

Section: Tolerabilitymentioning

confidence: 99%

Optimal Use of Beta-Blockers for Congestive Heart Failure

Lee

Baek

2016

Circ J

View full text Add to dashboard Cite

Genetic Tailoring of Pharmacotherapy in Heart Failure: Optimize the Old, While We Wait for Something New

Cited by 23 publications

References 74 publications

Opinions, hopes and concerns regarding pharmacogenomics: a comparison of healthy individuals, heart failure patients and heart transplant recipients

Opinions, hopes and concerns regarding pharmacogenomics: a comparison of healthy individuals, heart failure patients and heart transplant recipients

Physicians’ Attitudes Toward Pharmacogenetic Testing Before and After Pharmacogenetic Education

Optimal Use of Beta-Blockers for Congestive Heart Failure

Contact Info

Product

Resources

About